# Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)

> **NCT04692155** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Alabama at Birmingham** · enrollment: 1 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Ublituximab
- **DRUG:** Umbralisib

## Key facts

- **NCT ID:** NCT04692155
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-31
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** FDA hold
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04692155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04692155, "Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04692155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*